peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

Amylin analog · 37 amino acids

Pramlintide

/PRAM-lin-tide/FDA-approved ingredient
Loading scientific anatomy…
Interactive anatomy · drag to rotate

02 · Consumer names

One ingredient.
Distinct products.

01

SymlinPen

Premeal subcutaneous injection

Adjunct to mealtime insulin in selected adults whose desired glucose control has not been achieved.

Find official label ↗

Product names are not synonyms for one another. Route, strength, indication, and instructions can differ. Compare with primary label

03 · Mechanism + use

What the molecule does,
and where the label stops.

What it does
Slows gastric emptying, suppresses inappropriate post-meal glucagon secretion, and increases satiety, reducing postprandial glucose excursions.Mechanism source
Labeled-use boundary
Used only in carefully selected insulin-treated patients who can follow glucose monitoring and insulin-adjustment instructions.Primary label

04 · Labeled safety

Risk belongs
beside benefit.

Boxed warning

Severe hypoglycemia can occur when pramlintide is used with insulin, especially in type 1 diabetes; risk-reduction instructions and patient selection are central to the label.Open boxed warning

Who should avoid it

  • Hypoglycemia unawareness
  • Confirmed gastroparesis
  • Serious hypersensitivity
Contraindications

More common effects

  • Nausea
  • Vomiting
  • Anorexia
  • Headache
Adverse reactions

Important serious risks

  • Severe insulin-induced hypoglycemia
  • Medication errors involving insulin
  • Delayed absorption of concomitant oral medicines
Warnings

This is a structured label summary, not a complete prescribing-information substitute and not a personalized risk estimate.

05 · Evidence interpretation

Claims with
their edges visible.

01

Post-meal glucose control

Trials evaluated pramlintide added to insulin regimens.

Supporting source
Evidence form
Randomized adjunctive trials
Keep in view
Benefit must be weighed against added injection and hypoglycemia complexity.
02

Risk-management is the profile

The boxed warning, selection criteria, education, and insulin reduction are inseparable from use.

Supporting source
Evidence form
Regulatory risk synthesis
Keep in view
This atlas is not a dosing tool.
03

Mechanism spans gut and brain

Gastric, glucagon, and satiety actions complement insulin.

Supporting source
Evidence form
Established pharmacology
Keep in view
Mechanism does not remove behavioral and monitoring requirements.

06 · Research universe

Reviewed anchors.
Live indexes.

The regulatory label anchors approved use and safety. PubMed and ClinicalTrials.gov expose the broader, continuously changing research universe without pretending every result has been reviewed.

  1. 01Regulatory label
    SymlinPen prescribing information

    DailyMed label including the boxed warning and patient-selection requirements.

    Open source ↗
  2. 02Literature index
    Every PubMed result for pramlintide

    Live National Library of Medicine literature search; results are not pre-screened or deduplicated.

    Open source ↗
  3. 03Trial registry
    Every registered study for pramlintide

    Live ClinicalTrials.gov search, including completed, active, and historical records.

    Open source ↗
  4. 04Chemical record
    pramlintide chemical record

    PubChem compound search from the National Library of Medicine.

    Open source ↗